HomeAI · summaries
Storia in 16 fonti
Eli Lilly, il farmaco anti-obesità che sfida la chirurgia bariatrica: fino al 28% di peso in meno e debutto nel 2027 | MilanoFinanza News
I pazienti che sono riusciti a tollerare per un anno e mezzo la dose più alta del farmaco Retatrutide hanno perso in media il 28,3% del loro peso corporeo. Batte il Wegovy di Novo Nordisk
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
nbcnews.com
People lost up to 85 pounds on Lilly’s experimental weight loss drug, company says
The results — the most weight loss ever seen in a medication trial — put the drug’s effectiveness on par with bariatric surgery.
- ·
cnbc.com
Eli Lilly says next-generation weight loss drug clears crucial obesity trial
The results bring Lilly one step closer to filing for approval of the injection, retatrutide, which works differently from existing injections and pills.
- ·
milanofinanza.it
Eli Lilly, il farmaco anti-obesità che sfida la chirurgia bariatrica: fino al 28% di peso in meno e debutto nel 2027 | MilanoFinanza News
I pazienti che sono riusciti a tollerare per un anno e mezzo la dose più alta del farmaco Retatrutide hanno perso in media il 28,3% del loro peso corporeo. Batte il Wegovy di Novo…
- ·
qz.com
Eli Lilly retatrutide Phase 3 obesity trial results 2026
The triple-hormone injection outpaced existing weight loss drugs and approached bariatric surgery outcomes in an 80-week study
- ·
thehindubusinessline.com
Eli Lilly says next-gen obesity drug helps patients lose 28% of body weight
Eli Lilly's retatrutide shows promise, helping obesity patients lose over 28% of their weight in a key trial.
- ·
eu.usatoday.com
New weight-loss shot more powerful than old GLP-1s, Eli Lilly says
Lilly said people on the next-generation weight loss medication across three different dosages achieved weight loss of 19% to 28%.
- ·
zerohedge.com
Lilly's Next-Gen Weight-Loss Drug Clears Trial With Near-Bariatric Surgery Results
"We're in a zone that's historically been associated with bariatric surgery, and you're getting it with a medicine."
- ·
valor.globo.com
Eli Lilly diz que novo medicamento ajuda pacientes com obesidade a perder 28% do peso corporal
Resultados do Retatrutida ao longo de um ano e meio, em um estudo, abrem caminho para que a empresa busque aprovação regulatória e lance o medicamento no próximo ano
- ·
washingtonexaminer.com
New Eli Lilly weight loss drug has dramatic effects in clinical trial
A new weight loss drug from Eli Lilly made patients lose 28% of their body weight on average, levels achieved only by surgery before.
- ·
time.com
A Next-Generation Drug Causes Dramatic Weight Loss, Eli Lilly Says
Retatrutide, an experimental injectable drug, targets three hormones related to weight loss.
- ·
economictimes.indiatimes.com
Eli Lilly’s obesity drug shows up to 30% weight loss in trial
Eli Lilly's new obesity drug retatrutide shows remarkable results. In a major trial, patients lost up to 30% of their body weight. This once-weekly injection targets multiple…
- ·
infobae.com
Un nuevo fármaco experimental de Eli Lilly reduce el peso un 30 % en un ensayo clínico
Un nuevo fármaco experimental de Eli Lilly reduce el peso un 30 % en un ensayo clínico
- ·
benzinga.com
Eli Lilly's Triple Hormone Obesity Drug Shows Significant Weight Loss - Eli Lilly (NYSE:LLY)
Eli Lilly says retatrutide helped obesity trial participants lose up to 28.3% body weight in the Phase 3 TRIUMPH-1 study.
- ·
upi.com
Eli Lilly: Next-gen weight loss drug may be more effective than others - UPI.com
Eli Lilly's weight loss drug retatrutide helped nearly half of participants in a phase 3 trial to lose more than 30% of their weight after two years.
- ·
expansion.com
La retatrutida de Eli Lilly reduce la obesidad en un 30% a los dos a�os de tratamiento
Los resultados preliminares del estudio TRIUMPH-1 confirman resultados anteriores en fase II de la retatrutida (LY3437943), f�rmaco en fase experimental de la familia de los…
- ·
g1.globo.com
Nova caneta contra obesidade leva pacientes a perder até 32 kg em estudo de fase 3 | G1
Retatrutida, molécula da Eli Lilly ainda em investigação, mostrou perda média de 28,3% do peso corporal em 80 semanas; resultado se aproxima de índices observados em cirurgias…